media release

AkzoNobel to sell Zeta Fraction biofunctional technology to Ashland

AkzoNobel today announced the sale of its biomaterials technology to Ashland Inc. The transaction is expected to be completed in the third quarter of this year.

The business is in its early phase of commercialization and the divestment of this biomaterials technology follows a strategic review of the business’ fit within AkzoNobel’s portfolio. This transaction will enable us to focus on our core technology platforms – specialty surfactants and polymers – and help reinforce our leadership position in both areas.

The biomaterials activities are focused on plant-based chemistry, which is used to develop products for various applications, such as high performance beauty technologies.

 

Contact for this publication

Media Relations

For media requests only
Contact for other questions